Orchard Therapeutics Announces Clinical Proof-of-Concept Data for Gene Therapy OTL-300 Demonstrating Efficacy in Transfusion-Dependent Beta-Thalassemia
April 29, 2019 07:00 ET
|
Orchard Therapeutics Limited
Study Used the GLOBE Lentiviral Vector and Treated Adult and Pediatric Patients with Severe Phenotypes At 12 Months Following Treatment, Eight of Nine Patients Had Reduced or Eliminated Need for...
Orchard Therapeutics Strengthens Commercial Leadership Team with Appointment of Francis Pang as Vice President of Global Market Access
April 26, 2019 07:00 ET
|
Orchard Therapeutics Limited
BOSTON and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of...
Orchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
April 25, 2019 07:00 ET
|
Orchard Therapeutics Limited
Program on Track for MAA and BLA Regulatory Submissions in 2021 Recent Lancet Hematology Publication Describes Encouraging Safety and Efficacy Data from Interim Analysis of OTL-103 Fresh Formulation...
Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting
April 15, 2019 07:00 ET
|
Orchard Therapeutics Limited
BOSTON and LONDON, April 15, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
March 27, 2019 07:00 ET
|
Orchard Therapeutics Limited
Compared to Natural History, Late Infantile Patients Demonstrated Gross Motor Function Scores Higher by 65 and 72 Percentage Points at 2- and 3-Years Post Gene Therapy; Early Juvenile Patients...
Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights
March 21, 2019 07:00 ET
|
Orchard Therapeutics Limited
Three Lead Programs for MLD, ADA-SCID and WAS on Track for Regulatory Filings Over the Next Three Years, with MLD and ADA-SCID Expected in 2020 Registrational Data Showing 100% Overall Survival and...
Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer
March 18, 2019 07:00 ET
|
Orchard Therapeutics Limited
BOSTON AND LONDON, March 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019
March 14, 2019 07:00 ET
|
Orchard Therapeutics Limited
BOSTON and LONDON, March 14, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
March 11, 2019 07:00 ET
|
Orchard Therapeutics Limited
BOSTON and LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019
March 04, 2019 07:00 ET
|
Orchard Therapeutics Limited
BOSTON and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...